BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES, Aug. 11, 2023 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). Class Period:…